ROBERT BAYLESS: Open Payments
NPI 1306555826 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,538 in 128 payments from 27 companies in 2025. Trend: 2023 $2,113 · 2024 $1,519 · 2025 $2,538
Food & beverage: $2,538
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $537 |
| Teva Pharmaceuticals USA, Inc. | 13 | $233 |
| Novo Nordisk Inc | 10 | $186 |
| AstraZeneca Pharmaceuticals LP | 8 | $186 |
| Otsuka America Pharmaceutical, Inc. | 9 | $178 |
| Amgen Inc. | 6 | $111 |
| PFIZER INC. | 6 | $104 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $101 |
| Janssen Pharmaceuticals, Inc | 3 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $91 |
Products named: REXULTI, AUSTEDO XR, QULIPTA, UBRELVY, AIRSUPRA, JARDIANCE, INVEGA SUSTENNA, CAPLYTA.
Industry payments across WA — which companies pay providers there.
